Date: 2017-08-10
Type of information: Research agreement
Compound: checkpoint fusion proteins
Company: Takeda Pharmaceutical (Japan) Shattuck Labs (USA - TX)
Therapeutic area: Cancer - Oncology
Type agreement: research - collaboration
Action mechanism:
- fusion protein/immunotherapy product. Shattuck Lab’s Agonist Redirected Checkpoint (ARC)™ platform combines two binding domains to create fusion proteins that potentially restore and enhance immune system function in a single construct. The ARC molecules block checkpoint molecules while simultaneously stimulating TNF superfamily co-stimulatory receptors on T-cells and innate cells, which are targets controlling the immune system and often dysregulated in cancers, thereby enabling combination immunotherapy with a single product.
Disease:
Details:
- • On August 10, 2017, Takeda Pharmaceutical and Shattuck Labs announced that they have entered into a research collaboration to explore and develop checkpoint fusion proteins that have the potential to become highly differentiated, next-generation immunotherapies. Under the terms of the collaboration agreement, Takeda will hold options for exclusive global development and commercialization rights for up to four molecules resulting from the collaboration.
- The collaboration will include two pre-clinical and four discovery stage programs. Takeda will provide funding for pre-clinical and clinical development and will have the option to take an exclusive license to further develop and commercialize up to four ARC molecules resulting from the collaboration. Additional terms of the collaboration are not disclosed. Takeda signed the collaboration agreement through its wholly-owned subsidiary, Millennium Pharmaceuticals.
Financial terms:
Latest news:
Is general: Yes
